16 apr: Første ordre i Emiraterne
16 apr: Nordea Bank udsteder nye Mini Futures
16-04-2019 12:46:43

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2019

Company Announcement

  • Net sales of DARZALEX in the first quarter of 2019 totaled USD 629 million

  • Genmab will receive royalties on worldwide sales from Janssen Biotech, Inc.

Copenhagen, Denmark; April 16, 2019 –

Genmab A/S (Nasdaq Copenhagen: GEN) announced today that worldwide net sales of DARZALEX (daratumumab) as reported by Johnson & Johnson were USD 629 million in the first quarter of 2019. Net sales were USD 352 million in the U.S. and USD 277 million in the rest of the world. Genmab will receive royalties on the worldwide net sales of DARZALEX under the exclusive worldwide license to Janssen Biotech, Inc. to develop, manufacture and commercialize DARZALEX.

About DARZALEX

®

(daratumumab)

DARZALEX® (daratumumab) injection for intravenous infusion is indicated in the United States in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor (PI); and as a monotherapy for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a PI and an immunomodulatory agent, or who are double-refractory to a PI and an immunomodulatory agent.1 DARZALEX is the first monoclonal antibody (mAb) to receive U.S. Food and Drug Administration (U.S. FDA) approval to treat multiple myeloma. DARZALEX is indicated in Europe in combination with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy; and as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a PI and an immunomodulatory agent and who have demonstrated disease progression on the last therapy. The option to split the first infusion of DARZALEX over two consecutive days has been approved in both Europe and the U.S. In Japan, DARZALEX is approved in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adults with relapsed or refractory multiple myeloma.  DARZALEX is the first human CD38 monoclonal antibody to reach the market in the United Stated, Europe and Japan.  For more information, visit www.DARZALEX.com.

Daratumumab is a human IgG1k monoclonal antibody (mAb) that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells.  Daratumumab triggers a person’s own immune system to attack the cancer cells, resulting in rapid tumor cell death through multiple immune-mediated mechanisms of action and through immunomodulatory effects, in addition to direct tumor cell death, via apoptosis (programmed cell death).1,2,3,4,5

Daratumumab is being developed by Janssen Biotech, Inc. under an exclusive worldwide license to develop, manufacture and commercialize daratumumab from Genmab. A comprehensive clinical development program for daratumumab is ongoing, including multiple Phase III studies in smoldering, relapsed and frontline multiple myeloma settings and in amyloidosis.  Additional studies are ongoing or planned to assess the potential of daratumumab in other malignant and pre-malignant diseases, such as NKT-cell lymphoma, B and T-ALL.  Daratumumab has received two Breakthrough Therapy Designations from the U.S. FDA, for multiple myeloma, as both a monotherapy and in combination with other therapies.

About Genmab

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.  Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications.  Daratumumab is in clinical development for additional multiple myeloma indications and other blood cancers.  A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis.  Genmab also has a broad clinical and pre-clinical product pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, the HexaBody® platform, which creates effector function enhanced antibodies and the HexElect®  platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products.  Genmab has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com.

Contact:          

Marisol Peron, Corporate Vice President, Communications & Investor Relations

T: +1 609 524 0065; E: mmp@genmab.com

For Investor Relations:

Andrew Carlsen, Senior Director, Investor Relations

T: +45 3377 9558; E: acn@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody®; HexElect®; and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® is a trademark of Janssen Pharmaceutica NV.

1 DARZALEX Prescribing information, February 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761036s016lbl.pdf Last accessed February 2019

2 De Weers, M et al. Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors. The Journal of Immunology. 2011; 186: 1840-1848.

3 Overdijk, MB, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015; 7: 311-21.

4Krejcik, MD et al. Daratumumab Depletes CD38+ Immune-regulatory Cells, Promotes T-cell Expansion, and Skews T-cell Repertoire in Multiple Myeloma. Blood. 2016; 128: 384-94.

5Jansen, JH  et al. Daratumumab, a human CD38 antibody induces apoptosis of myeloma tumor cells via Fc receptor-mediated crosslinking. Blood. 2012; 120(21): abstract 2974.

Company Announcement no. 19

CVR no. 2102 3884

LEI Code 529900MTJPDPE4MHJ122

Genmab A/S

Kalvebod Brygge 43

1560 Copenhagen V

Denmark

Attachment

logo.jpg

Relateret indhold
16 sep - 
Mandagens aktier: Svingende Lundbeck endte lavere i rød..
16 sep - 
Aktier/middag: Lundbeck vender rundt og topper rødt C25..
16 sep - 
Aktier/åbning: Lundbeck helt i bund på milliardopkøb i ..
Relateret debat
19 sep - 
Det var på det gamle Nordnet, men nu kører det fint ige..
19 sep - 
Gl. Nordnet kører fint. BB
19 sep - 
Tror du kigger hos Nordnet? Genmab er handlet mange gan..
Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
16 sep
GEN
GENMAB/GUGGENHEIM: LØFTER KURSMÅLET MED 12,4 PCT. 06:36 Finanshuset Guggenheim Securities løfter sit..
9
13 sep
GEN
13.9.19: “Novartis' ofatumumab to be 'strong' competitor to Roche drug, says Deutsche Bank Deutsche ..
5
13 sep
GEN
BofA/Merrill analyst Sachin Jain upgraded Genmab to Buy from Neutral with an increased price target ..
2
13 sep
GEN
Vi kunne jo starte med 1000 hver, men det flytter nok ikke det store. Tror på Genmab er et guldæg, e..
1
13 sep
GEN
Mit svar var et forsøg på at besvare QueenMary og IKKE nogen anbefaling. Har desværre heller ikke se..
1
13 sep
GEN
GENMAB: POSITIVE RESULTATER I KOMBINATIONSSTUDIE MED DARZALEX - NY 16:22Biotekselskabet Genmab kan g..
1
13 sep
GEN
Kan du så ikke bare købe 20.000 stk. så sker der nok lidt med kursen.   Taastrup 
1
13 sep
GEN
Når man skimmer de resultater, der deles på Twitter, lader det til at der er tale om et meget succes..
1
13 sep
GEN
Company Announcement Details from the ASCLEPIOS I & II studies of subcutaneous ofatumumab (OMB157) ..
1
13 sep
GEN
Hvad skete der lige kl.14:14...der stiger aktien lige 26 point, for derefter at smide 40 igen.   Er ..
1

OECD sænker global vækstprognose for de kommende år

19-09-2019 11:20:24
Organisationen for Økonomisk Samarbejde og Udvikling (OECD) sænker sin globale vækstprognose for de kommende år, idet organisationen nu ser yderligere risici i verdensøkonomien.OECD venter nu en global vækst i bruttonationalproduktet (BNP) på 2,9 pct. i år og 3,0 pct. næste år.Det er en nedrevidering fra henholdsvis 3,2 pct. og 3,4 pct. i den seneste prognose.For USA er vækstprognosen sænket til 2..

Aktier/tendens: Udsigt til rød start ovenpå FED-møde

19-09-2019 08:25:07
Der er umiddelbart udsigt til små fald fra starten af den danske aktiehandel torsdag, hvor øjne og ører kan rette sig mod Ørsted, Simcorp og Sydbank. Dermed følger markedet onsdagens tendens efter tilbagegang efter rentemødet i den amerikanske centralbank, Federal Reserve (Fed).Japanske aktier ligger højere, futures på amerikanske aktier ligger op til 0,4 pct. lavere, mens DAX-futuren ligger 0,1 p..

Lars Christensens Verden - Episode 26: Sidste uges quant quake varsler nye tider på de finansielle markeder

Relaterede nyheder
18-09-2019 19:17:00
Begivenheden er af nogle blevet omtalt som et jordskælv i de globale markeder, og nej det var ikke ECB's seneste rentebeslutning eller den renteforhøjelse eller -nedsættelse, Fed annoncerer onsdag aften, dansk tid. Det er heller ikke oliepriserne, der har bevæget sig voldsomt ovenpå weekendens angreb på de saudiske olieinstallationer og Trumps Iran-tweets i kølvandet herpå, men derimod det såkaldt..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Novo Nordisk får markedet til at holde vejret
2
Novo står foran stor eksamen - kan åbne dør til 200 milliarder - GENT
3
Novo misser primært endemål i sammenligningsstudie med fransk rival
4
Ørsted vælger kæmpe GE-mølle: "Overraskende det sker så hurtigt"
5
Vestas/JPMorgan: Skærer 40 kr. af kursmålet til 445 kr.

Relaterede aktiekurser

Genmab A/S 1.380,00 -0,2% Fald i aktiekurs

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
20. september 2019 09:59:29
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190829.2 - EUROWEB3 - 2019-09-20 09:59:29 - 2019-09-20 09:59:29 - 1 - Website: OKAY